| Name | Title | Contact Details |
|---|
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
CRB is a Oreland, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EyeMarker Systems is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Learn about how Johnson & Johnson Vision is committed to addressing the world-wide problems of vision impairment through prevention and treatment.
Healthpoint Biotherapeutics is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.